Metabolomics techniques for nanotoxicity investigations

Bioanalysis

Volumn 7, Issue 12, 2015, Pages 1527-1544

  Lv, Mengying ^a   Huang, Wanqiu ^a   Chen, Zhipeng ^b   Jiang, Hulin ^a   Chen, Jiaqing ^a   Tian, Yuan ^a   Zhang, Zunjian ^a   Xu, Fengguo ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER NANOPARTICLE; NANOPARTICLE; POLYSTYRENE; POLYVINYL ACETATE; SILICA NANOPARTICLE; SILVER NANOPARTICLE; SINGLE WALLED NANOTUBE; SOLID LIPID NANOPARTICLE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TITANIUM DIOXIDE NANOPARTICLE; ZINC OXIDE NANOPARTICLE; NANOMATERIAL;

CYTOTOXICITY; DISCRIMINANT ANALYSIS; GAS CHROMATOGRAPHY; GENOTOXICITY; HUMAN; INFLAMMATION; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; METABOLISM; METABOLOMICS; NANOTOXICOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; OXIDATIVE STRESS; PARTIAL LEAST SQUARES REGRESSION; PHYSICAL CHEMISTRY; REVIEW; CHEMISTRY; NANOTECHNOLOGY; TOXICITY TESTING;

HUMANS; METABOLIC NETWORKS AND PATHWAYS; METABOLOMICS; NANOPARTICLES; NANOSTRUCTURES; NANOTECHNOLOGY; TOXICITY TESTS;

EID: 84937040414     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.15.83     Document Type: Review

References (136)

1. Klaper R, Arndt D, Bozich J et al. Molecular interactions of nanomaterials and organisms: defning biomarkers for toxicity and high-throughput screening using traditional and next-generation sequencing approaches. Analyst 139(5), 882-895 (2014).
2. Nel A, Xia T, Madler L et al. Toxic potential of materials at the nanolevel. Science 311(5761), 622-627 (2006).
3. Donaldson K, Stone V, Tran CL et al. Nanotoxicology J. Occup. Environ. Med. 61(9), 727-728 (2004).
4. Oberdörster G, Stone V, Donaldson K. Toxicology of nanoparticles: a historical perspective. Nanotoxicology 1(1), 2-25 (2007).
5. Elsaesser A, Howard CV. Toxicology of nanoparticles. Adv. Drug Deliver. Rev. 64(2), 129-137 (2012).
6. Yan L, Nie W, Parker T et al. MS-based metabolomics facilitates the discovery of in vivo functional small molecules with a diversity of biological contexts. Future Med. Chem. 5 (16), 1953-1965 (2013).
7. Patti GJ, Yanes O, Siuzdak G. Innovation: metabolomics: the apogee of the omics trilogy. Nat. Rev. Mol. Cell Biol. 13(4), 263-269 (2012).
8. Keun HC. Metabonomic modeling of drug toxicity. Pharmacol. Ther. 109(1-2), 92-106 (2006).
9. Bain JR, Stevens RD, Wenner BR et al. Metabolomics applied to diabetes research: moving from information to knowledge. Diabetes 58(11), 2429-2443 (2009).
10. Fiehn O. Metabolomics-the link between genotypes and phenotypes. Plant. Mol. Biol. 48(1-2), 155-171 (2002).
11. Beckonert O, Keun HC, Ebbels TM et al. Metabolic profling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat. Protoc. 2(11), 2692-2703 (2007).
12. Simón-Manso Y, Lowenthal MS, Kilpatrick LE et al. Metabolite profling of a NIST Standard Reference Material for human plasma (SRM 1950): GC-MS, LC-MS, NMR, and clinical laboratory analyses, libraries, and web-based resources. Anal. Chem. 85(24), 11725-11731 (2013).
13. A J, Trygg J, Gullberg J et al. Extraction and GC/MS analysis of the human blood plasma metabolome. Anal. Chem. 77(24), 8086-8094 (2005).
14. Mapelli V, Olsson L, Nielsen J. Metabolic footprinting in microbiology: methods and applications in functional genomics and biotechnology. Trends. Biotechnol. 26(9), 490-497 (2008).
15. Smith CA, Want EJ, O'maille G et al. XCMS: processing mass spectrometry data for metabolite profling using nonlinear peak alignment, matching, and identifcation. Anal. Chem. 78(3), 779-787 (2006).
16. Trygg J, Holmes E, Lundstedt T. Chemometrics in metabonomics. J. Proteome. Res. 6(2), 469-479 (2007).
17. Goodarzi M, Russell PJ, Vander HY. Similarity analyses of chromatographic herbal fngerprints: a review. Anal. Chim. Acta 804, 16-28 (2013).
18. Chan EC, Pasikanti KK, Nicholson JK. Global urinary metabolic profling procedures using gas chromatography-mass spectrometry. Nat. Protoc. 6(10), 1483-1499 (2011).
19. Wishart DS, Knox C, Guo AC et al. HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res. 37, D603-D610 (2009).
20. Robertson DG, Watkins PB, Reily MD. Metabolomics in toxicology: preclinical and clinical applications. Toxicol. Sci. 120(Suppl. 1), S146-S170 (2011).
21. Lu W, Bennett BD, Rabinowitz JD. Analytical strategies for LC-MS-based targeted metabolomics. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 871(2), 236-242 (2008).
22. Wei R, Li G, Seymour AB. High-throughput and multiplexed LC/MS/MRM method for targeted metabolomics. Anal. Chem. 82(13), 5527-5533 (2010).
23. Schmerler D, Neugebauer S, Ludewig K et al. Targeted metabolomics for discrimination of systemic infammatory disorders in critically ill patients. J. Lipid Res. 53(7), 1369-1375 (2012).
24. Zhong D, Chen X, Gu J et al. Applications of liquid chromatography-tandem mass spectrometry in drug and biomedical analyses. Clin. Chim. Acta 313(1-2), 147-150 (2001).
25. Lu X, Tian Y, Zhao Q et al. Integrated metabonomics analysis of the size-response relationship of silica nanoparticles-induced toxicity in mice. Nanotechnology 22 (5), 055101 (2011).
26. Feng J, Li J, Wu H et al. Metabolic responses of HeLa cells to silica nanoparticles by NMR-based metabolomic analyses. Metabolomics 9(4), 874-886 (2013).
27. 2 nanoparticles in MRC-5 human fetal lung fbroblasts. Adv. Healthc. Mater. 1(6), 779-784 (2012).
28. Parveen A, Rizvi S, Gupta A et al. NMR-based metabonomics study of sub-acute hepatotoxicity induced by silica nanoparticles in rats after intranasal exposure. Cell. Mol. Biol. 58(1), 196-203 (2012).
29. Irfan A, Cauchi M, Edmands W et al. Assessment of temporal dose-toxicity relationship of fumed silica nanoparticle in human lung A549 cells by conventional cytotoxicity and 1H-NMR-based extracellular metabonomic assays. Toxicol. Sci. 138(2), 354-364 (2014).
30. Bu Q, Yan G, Deng P et al. NMR-based metabonomic study of the sub-acute toxicity of titanium dioxide nanoparticles in rats after oral administration. Nanotechnology 21(12), 125105 (2010).
31. Jin C, Liu Y, Sun L et al. Metabolic profling reveals disorder of carbohydrate metabolism in mouse fbroblast cells induced by titanium dioxide nanoparticles. J. Appl. Toxicol. 33(12), 1442-1450 (2013).
32. Tang M, Zhang T, Xue Y et al. Dose dependent in vivo metabolic characteristics of titanium dioxide nanoparticles. J. Nanosci. Nanotechnol. 10 (12), 8575-8583 (2010).
33. 2 nanoparticles. J. Nanosci. Nanotechnol. 11(4), 3065-3074 (2011).
34. 2 nanoparticle-induced cytotoxicity study. Chromatographia 75(21-22), 1301-1310 (2012).
35. 2 nanoparticles in mouse fbroblast cells: from the perspective of perturbations in amino acid metabolism. Toxicol. Mech. Method. 24(7), 461-469 (2014).
36. 2 nanomaterials. Environ. Sci. 1(5), 466-477 (2014).
37. Hadrup N, Lam HR, Loeschner K et al. Nanoparticulate silver increases uric acid and allantoin excretion in rats, as identifed by metabolomics. J. Appl. Toxicol. 32(11), 929-933 (2012).
38. Kim S, Kim S, Lee S et al. Characterization of the effects of silver nanoparticles on liver cell using HR-MAS NMR spectroscopy. Bull. Korean Chem. Soc. 32(6), 2021-2026 (2011).
39. Lin B, Zhang H, Lin Z et al. Studies of single-walled carbon nanotubes-induced hepatotoxicity by NMR-based metabonomics of rat blood plasma and liver extracts. Nanoscale Res. Lett. 8(1), 1-11 (2013).
40. Yan G, Huang Y, Bu Q et al. Zinc oxide nanoparticles cause nephrotoxicity and kidney metabolism alterations in rats. J. Environ. Sci. Heal. A. 47(4), 577-588 (2012).
41. Lei R, Wu C, Yang B et al. Integrated metabolomic analysis of the nano-sized copper particle-induced hepatotoxicity and nephrotoxicity in rats: a rapid in vivo screening method for nanotoxicity. Toxicol. Appl. Pharmacol. 232(2), 292-301 (2008).
42. Li J, Zhao Z, Feng J et al. Understanding the metabolic fate and assessing the biosafety of MnO nanoparticles by metabonomic analysis. Nanotechnology 24 (45), 455102 (2013).
43. Li J, Zhou Z, Feng J et al. NMR-based metabonomic analysis of MnO-embedded iron oxide nanoparticles as potential dual-modal contrast agents. J. Nanopart. Res. 16 (5), 1-16 (2014).
44. Nazari P, Dowlatabadi BR, Mofd MR et al. The antimicrobial effects and metabolomic footprinting of carboxyl-capped bismuth nanoparticles against Helicobacter pylori. Appl. Biochem. Biotech. 172(2), 570-579 (2014).
45. Feng J, Liu H, Zhang L et al. An insight into the metabolic responses of ultra-small superparamagnetic particles of iron oxide using metabonomic analysis of biofuids. Nanotechnology 21(39), 395101 (2010).
46. Shim W, Paik MJ, Nguyen DT et al. Analysis of changes in gene expression and metabolic profles induced by silica-coated magnetic nanoparticles. ACS Nano 6 (9), 7665-7680 (2012).
47. Dailey LA, Hernandez PR, Casas-Ferreira AM et al. Adenosine monophosphate is elevated in the bronchoalveolar lavage fuid of mice with acute respiratory toxicity induced by nanoparticles with high surface hydrophobicity. Nanotoxicology doi:10.3109/17435390.2014.894150 (2014) (Epub ahead of print).
48. Zanin H, Hollanda LM, Ceragioli HJ et al. Carbon nanoparticles for gene transfection in eukaryotic cell lines. Mat. Sci. Eng. C. Mater. 39, 359-370 (2014).
49. Qhobosheane M, Santra S, Zhang P et al. Biochemically functionalized silica nanoparticles. Analyst 126(8), 1274-1278 (2001).
50. 2 nanoparticles induce cytotoxicity and protein expression alteration in HaCaT cells. Part. Fibre Toxicol. 7(1), 1 (2010).
51. Chen J, Dong X, Zhao J et al. In vivo acute toxicity of titanium dioxide nanoparticles to mice after intraperitioneal injection. J. Appl. Toxicol. 29(4), 330-337 (2009).
52. Wang J, Zhou G, Chen C et al. Acute toxicity and biodistribution of different sized titanium dioxide particles in mice after oral administration. Toxicol. Lett. 168(2), 176-185 (2007).
53. 2 nanoparticles in hairless mice and porcine skin after subchronic dermal exposure. Toxicol. Lett. 191(1), 1-8 (2009).
54. Alexander JW. History of the medical use of silver. Surg. Infect. 10(3), 289-292 (2009).
55. Rai M, Yadav A, Gade A. Silver nanoparticles as a new generation of antimicrobials. Biotechnol. Adv. 27(1), 76-83 (2009).
56. Wijnhoven SWP, Peijnenburg WJGM, Herberts CA et al. Nano-silver-a review of available data and knowledge gaps in human and environmental risk assessment. Nanotoxicology 3(2), 109-138 (2009).
57. Kim YS, Song MY, Park JD et al. Subchronic oral toxicity of silver nanoparticles. Part. Fibre Toxicol. 7(1), 20 (2010).
58. Carlson C, Hussain SM, Schrand AM et al. Unique cellular interaction of silver nanoparticles: size-dependent generation of reactive oxygen species. J. Phys. Chem. B. 112(43), 13608-13619 (2008).
59. Xia J, Mandal R, Sinelnikov IV et al. MetaboAnalyst 2.0-a comprehensive server for metabolomic data analysis. Nucleic Acids Res. 40, W127-W133 (2012).
60. Kermanizadeh A, Gaiser BK, Hutchison GR et al. An in vitro liver model-assessing oxidative stress and genotoxicity following exposure of hepatocytes to a panel of engineered nanomaterials. Part. Fibre Toxicol. 9(1), 28 (2012).
61. Meng H, Xia T, George S et al. A predictive toxicological paradigm for the safety assessment of nanomaterials. ACS Nano 3(7), 1620-1627 (2009).
62. Napierska D, Thomassen LC, Lison D et al. The nanosilica hazard: another variable entity. Part. Fibre Toxicol. 7(1), 39 (2010).
63. Oberdörster G, Maynard A, Donaldson K et al. Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy. Part. Fibre Toxicol. 2, 8 (2005).
64. Sayes CM, Warheit DB. Characterization of nanomaterials for toxicity assessment. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 1(6), 660-670 (2009).
65. Boverhof DR, David RM. Nanomaterial characterization: considerations and needs for hazard assessment and safety evaluation. Anal. Bioanal. Chem. 396(3), 953-961 (2010).
66. Dhawan A, Sharma V. Toxicity assessment of nanomaterials: methods and challenges. Anal. Bioanal. Chem. 398(2), 589-605 (2010).
67. Doak S H, Griffths S M, Manshian B et al. Confounding experimental considerations in nanogenotoxicology Mutagenesis 24 (4), 285-293 (2009).
68. Tenzer S, Docter D, Kuharev J et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat. Nanotechnol. 8(10), 772-781 (2013).
69. Veranth J M, Kaser E G, Veranth M M et al. Cytokine responses of human lung cells (BEAS-2B) treated with micron-sized and nanoparticles of metal oxides compared with soil dusts. Part. Fibre Toxicol. 4, 2 (2007).
70. Kroll A, Pillukat M H, Hahn D et al. Current in vitro methods in nanoparticle risk assessment: limitations and challenges. Eur. J Pharm. Biopharm. 72(2), 370-377 (2009).
71. Monteiro-Riviere N A, Inman A O, Zhang L W. Limitations and relative utility of screening assays to assess engineered nanoparticle toxicity in a human cell line. Toxicol. Appl. Pharm. 234(2), 222-235 (2009).
72. Xiao L, Gu L, Howell SB et al. Porous silicon nanoparticle photosensitizers for singlet oxygen and their phototoxicity against cancer cells. ACS Nano 5 (5), 3651-3659 (2011).
73. Karlsson HL, Cronholm P, Hedberg Y et al. Cell membrane damage and protein interaction induced by copper containing nanoparticles-importance of the metal release process. Toxicology 313(1), 59-69 (2013).
74. Marquis BJ, Love SA, Braun KL et al. Analytical methods to assess nanoparticle toxicity. Analyst 134(3), 425-439 (2009).
75. Vecchio G, Galeone A, Brunetti V et al. Mutagenic effects of gold nanoparticles induce aberrant phenotypes in Drosophila melanogaster. Nanomedicine 8(1), 1-7 (2012).
76. 2) nanoparticles at two trophic levels: plant and human lymphocytes. Chemosphere 81(10), 1253-1262 (2010).
77. Vanos R, Lildhar LL, Lehoux EA et al. In vitro macrophage response to nanometer-size chromium oxide particles. J. Biomed. Mater. Res. B. 102(1), 149-159 (2014).
78. Liu H, Yang D, Yang H et al. Comparative study of respiratory tract immune toxicity induced by three sterilisation nanoparticles: silver, zinc oxide and titanium dioxide. J. Hazard. Mater. 248, 478-486 (2013).
79. KEGG pathway database. www.genome.jp
80. Calero M, Gutiérrez L, Salas G et al. Effcient and safe internalization of magnetic iron oxide nanoparticles: two fundamental requirements for biomedical applications. Nanomedicine 10(4), 733-743 (2014).
81. Nel A. Air pollution-related illness: effects of particles. Science 308(5723), 804-806 (2005).
82. 2 nanoparticles via p38-Nrf-2 signaling pathway in human bronchial epithelial cell, Beas-2B. Toxicol. Lett. 187(2), 77-83 (2009).
83. Völker C, Kämpken I, Boedicker C et al. Toxicity of silver nanoparticles and ionic silver: comparison of adverse effects and potential toxicity mechanisms in the freshwater clam Sphaerium corneum. Nanotoxicology 1-9 (2014)(Epub ahead of print).
84. Chen Z, Meng H, Xing G et al. Acute toxicological effects of copper nanoparticles in vivo. Toxicol. Lett. 163(2), 109-120 (2006).
85. 2) nanoparticles. Nanotoxicology 8(2), 132-141 (2014).
86. Kanakia S, Toussaint JD, Mullick CS et al. Dose ranging, expanded acute toxicity and safety pharmacology studies for intravenously administered functionalized graphene nanoparticle formulations. Biomaterials 35(25), 7022-7031 (2014).
87. Oberdörster G, Oberdörster E, Oberdörster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafne particles. Environ. Health. Persp. 113(7), 823-839 (2005).
88. Borzelleca JF. Paracelsus: herald of modern toxicology. Toxicol. Sci. 53(1), 2-4 (2000).
89. Buford M C, Hamilton Jr R F, Holian A. A comparison of dispersing media for various engineered carbon nanoparticles. Part. Fibre Toxicol. 4(1), 1-9 (2007).
90. Tan Y, Yin P, Tang L et al. Metabolomics study of stepwise hepatocarcinogenesis from the model rats to patients: potential biomarkers effective for small hepatocellular carcinoma diagnosis. Mol. Cell Proteomics 11(2), M111.010694 (2012).
91. Huang Y, Tian Y, Li G et al. Discovery of safety biomarkers for realgar in rat urine using UFLC-IT-TOF/MS and 1H NMR based metabolomics. Anal. Bioanal. Chem. 405 (14), 4811-4822 (2013).
92. Blechinger J, Bauer AT, Torrano AA et al. Uptake kinetics and nanotoxicity of silica nanoparticles are cell type dependent. Small 9(23), 3970-3980, 3906 (2013).
93. Duarte IF, Rocha CM, Gil AM. Metabolic profling of biofuids: potential in lung cancer screening and diagnosis. Expert Rev. Mol. Diagn. 13(7), 737-748 (2013).
94. Zhang A, Sun H, Wang P et al. Recent and potential developments of biofuid analyses in metabolomics. J. Proteomics 75(4), 1079-1088 (2012)
95. Naz S, Moreira dos Santos D C, García A et al. Analytical protocols based on LC-MS, GC-MS and CE-MS for nontargeted metabolomics of biological tissues. Bioanalysis 6(12), 1657-1677 (2014).
96. Joyce AR, Palsson B. The model organism as a system: integrating 'omics' data sets. Nat. Rev. Mol. Cell. Biol. 7(3), 198-210 (2006).
97. Heijne WH, Kienhuis AS, Van Ommen B et al. Systems toxicology: applications of toxicogenomics, transcriptomics, proteomics and metabolomics in toxicology. Expert Rev. Proteomics 2(5), 767-780 (2005).
98. Holmes E, Wilson ID, Nicholson JK. Metabolic phenotyping in health and disease. Cell 134(5), 714-717 (2008).
99. Zhang A, Sun H, Wang X. Serum metabolomics as a novel diagnostic approach for disease: a systematic review. Anal. Bioanal. Chem. 404(4), 1239-1245 (2012).
100. Mortishire-Smith RJ, Skiles GL, Lawrence JW et al. Use of metabonomics to identify impaired fatty acid metabolism as the mechanism of a drug-induced toxicity. Chem. Res. Toxicol. 17(2), 165-173 (2004).
101. Fengguo Xu, Li Zou, Ong CN. Experiment-originated variations, and multi-peak and multi-origination phenomena in derivatization-based GC-MS. Metabolomics 29, 269-280 (2010).
102. Gika HG, Wilson I. Global metabolic profling for the study of alcohol-related disorders. Bioanalysis 6(1), 59-77 (2014).
103. Naz S, García A, Barbas C. Multiplatform analytical methodology for metabolic fngerprinting of lung tissue. Anal. Chem. 85(22), 10941-10948 (2013).
104. Edwards LM, Lawler NG, Nikolic SB et al. Metabolomics reveals increased isoleukotoxin diol (12, 13-DHOME) in human plasma after acute Intralipid infusion. J. Lipid Res. 53(9), 1979-1986 (2012).
105. Mandal R, Guo AC, Chaudhary KK et al. Multi-platform characterization of the human cerebrospinal fuid metabolome: a comprehensive and quantitative update. Genome Med. 4(4), 38 (2012).
106. Maher AD, Zirah SF, Holmes E et al. Experimental and analytical variation in human urine in 1H NMR spectroscopy-based metabolic phenotyping studies. Anal. Chem. 79(14), 5204-5211 (2007).
107. Wishart DS, Lewis MJ, Morrissey JA et al. The human cerebrospinal fuid metabolome. J. Chromatogr. B. 871(2), 164-173 (2008).
108. Gowda GA. Human bile as a rich source of biomarkers for hepatopancreatobiliary cancers. Biomark. Med. 4(2), 299-314 (2010).
109. Koh Y, Pasikanti KK, Yap CW et al. Comparative evaluation of software for retention time alignment of gas chromatography/time-of-fight mass spectrometry-based metabonomic data. J. Chromatogr. A. 1217(52), 8308-8316 (2010).
110. Madsen R, Lundstedt T, Trygg J. Chemometrics in metabolomics-a review in human disease diagnosis. Anal. Chim. Acta 659(1-2), 23-33 (2010).
111. Pierce KM, Hoggard JC, Mohler RE et al. Recent advancements in comprehensive two-dimensional separations with chemometrics. J. Chromatogr. A. 1184(1-2), 341-352 (2008).
112. Xia J, Wishart DS. Metabolomic data processing, analysis, and interpretation using MetaboAnalyst. Curr. Protoc. Bioinform. 14 (14), 10 (2011).
113. Kanehisa M, Goto S, Sato Y et al. Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic Acids Res. 42, D199-D205 (2014).
114. Zhu ZJ, Schultz AW, Wang J et al. Liquid chromatography quadrupole time-of-fight mass spectrometry characterization of metabolites guided by the METLIN database. Nat. Protoc. 8(3), 451-460 (2013).
115. Horai H, Arita M, Kanaya S et al. MassBank: a public repository for sharing mass spectral data for life sciences. J. Mass Spectrom. 45(7), 703-714 (2010).
116. Buescher JM, Moco S, Sauer U et al. Ultrahigh performance liquid chromatography-tandem mass spectrometry method for fast and robust quantifcation of anionic and aromatic metabolites. Anal. Chem. 82(11), 4403-4412 (2010).
117. Bajad SU, Lu W, Kimball EH et al. Separation and quantitation of water soluble cellular metabolites by hydrophilic interaction chromatography-tandem mass spectrometry. J. Chromatogr. A. 1125(1), 76-88 (2006).
118. Tait AD, Abbs D, Teale P et al. Gas chromatographic and gas chromatographic/tandem mass spectrometric characterization of precursors on the sesterterpene pathway for steroid biosynthesis. Biomed. Environ. Mass Spectrom. 18(8), 572-575 (1989).
119. Hernández F, Sancho JV, Pozo OJ. Critical review of the application of liquid chromatography/mass spectrometry to the determination of pesticide residues in biological samples. Anal. Bioanal. Chem. 382(4), 934-946 (2005).
120. Milgroom A, Intrator M, Madhavan K et al. Mesoporous silica nanoparticles as a breast-cancer targeting ultrasound contrast agent. Colloid Surf. B 116, 652-657 (2014).
121. Yang KN, Zhang CQ, Wang W et al. pH-responsive mesoporous silica nanoparticles employed in controlled drug delivery systems for cancer treatment. Cancer Biol. Med. 11(1), 34-43 (2014).
122. 2 nanoparticles exposure as an early indicator of cytotoxicity. J. Nanobiotechnology 9, 29 (2011).
123. Lin W, Huang Y W, Zhou XD et al. In vitro toxicity of silica nanoparticles in human lung cancer cells. Toxicol. Appl. Pharmacol. 217(3), 252-259 (2006).
124. Jaganathan H, Godin B. Biocompatibility assessment of Si-based nano-and micro-particles. Adv. Drug. Deliv. Rev. 64 (15), 1800-1819 (2012).
125. Xia T, Kovochich M, Brant J et al. Comparison of the abilities of ambient and manufactured nanoparticles to induce cellular toxicity according to an oxidative stress paradigm. Nano Lett. 6(8), 1794-1807 (2006).
126. Xia T, Kovochich M, Liong M et al. Comparison of the mechanism of toxicity of zinc oxide and cerium oxide nanoparticles based on dissolution and oxidative stress properties. ACS Nano 2(10), 2121-2134 (2008).
127. Mueller NC, Nowack B. Exposure modeling of engineered nanoparticles in the environment. Environ. Sci. Technol. 42(12), 4447-4453 (2008).
128. Park B, Donaldson K, Duffn R et al. Hazard and risk assessment of a nanoparticulate cerium oxide-based diesel fuel additive-a case study. Inhal. Toxicol. 20(6), 547-566 (2008).
129. Wörle-Knirsch J M, Pulskamp K, Krug H F. Oops they did it again! Carbon nanotubes hoax scientists in viability assays. Nano Lett. 6(6), 1261-1268 (2006).
130. Belyanskaya L, Manser P, Spohn P et al. The reliability and limits of the MTT reduction assay for carbon nanotubes-cell interaction. Carbon 45(13), 2643-2648 (2007).
131. Tian L, Kim HS, Kim H et al. Changes in metabolic markers in insulin-producing β-cells during hypoxia-induced cell death as studied by NMR metabolomics. J. Proteome Res. 12(8), 3738-3745 (2013).
132. Kettler K, Veltman K, Van de Meent D et al. Cellular uptake of nanoparticles as determined by particle properties, experimental conditions, and cell type. Environ. Toxicol. Chem. 33(3), 481-492 (2014).
133. Stepkowski TM, Brzóska K, Kruszewski M. Silver nanoparticles induced changes in the expression of NF-κB related genes are cell type specifc and related to the basal activity of NF-κB. Toxicol. In. Vitro. 28(4), 473-478 (2014).
134. Shalhoub J, Sikkel MB, Davies KJ et al. Systems biology of human atherosclerosis. Vasc. Endovascular Surg. 48(1), 5-17 (2014).
135. Hur M, Campbell AA, Almeida-De-Macedo M et al. A global approach to analysis and interpretation of metabolic data for plant natural product discovery. Nat. Prod. Rep. 30(4), 565-583 (2013).
136. Cho K, Shibato J, Agrawal GK et al. Integrated transcriptomics, proteomics, and metabolomics analyses to survey ozone responses in the leaves of rice seedling. J. Proteome Res. 7(7), 2980-2998 (2008).